Advertisement

Sentinel node tumour burden quantified based on cytokeratin 19 mRNA copy number predicts non-sentinel node metastases in breast cancer: Molecular whole-node analysis of all removed nodes

  • Tomo Osako
    Correspondence
    Corresponding author at: Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. Tel.: +81 3 3570 0559; fax: +81 3 3570 0558.
    Affiliations
    Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan

    Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
    Search for articles by this author
  • Takuji Iwase
    Affiliations
    Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
    Search for articles by this author
  • Kiyomi Kimura
    Affiliations
    Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
    Search for articles by this author
  • Rie Horii
    Affiliations
    Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
    Search for articles by this author
  • Futoshi Akiyama
    Affiliations
    Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
    Search for articles by this author
Published:December 20, 2012DOI:https://doi.org/10.1016/j.ejca.2012.11.022

      Abstract

      Objective

      The one-step nucleic acid amplification (OSNA) assay can assess an entire lymph node and detect clinically relevant metastases quantified based on cytokeratin 19 (CK19) mRNA copy number. The OSNA assay of all sentinel lymph nodes (SNs) and non-sentinel nodes (non-SNs) allows for the accurate measurement of tumour burden in either situation. We aim to reveal the usefulness of the OSNA assay regarding the prediction of non-SN metastasis.

      Methods

      The subjects consisted of 185 breast cancer patients who underwent axillary dissection after a metastatic SN biopsy and whose SNs and non-SNs were examined using the OSNA whole-node assay between 2009 and 2011. The non-SN tumour burden was classified as macrometastasis (CK19 mRNA ⩾5000 copies/μl) or micrometastasis (250–5000 copies/μl). The relationship between SN and non-SN tumour burdens and predictors of non-SN metastasis were investigated.

      Results

      Among these 185 patients, 38 patients (20.5%) had macrometastasis and 58 (31.4%) had micrometastasis only in the non-SNs. Non-SN macrometastasis rates increased in direct proportion to the SN copy number: approximately 5% in patients with SNs with 250–500 copies; 20%, 500–5000 copies and 30%, ⩾5000 copies. However, non-SN micrometastasis rates were approximately 30% regardless of the SN copy number. In multivariate analyses, the mean SN copy number, number of macrometastatic SN and lymphovascular invasion were significant for identifying non-SN macrometastases.

      Conclusions

      The SN tumour burden quantified using the OSNA assay predicts non-SN metastases. A novel mathematical model to predict the non-SN tumour burden can be generated using the results of the OSNA assay.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lyman G.H.
        • Giuliano A.E.
        • Somerfield M.R.
        • et al.
        American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
        J Clin Oncol. 2005; 23: 7703-7720
        • Giuliano A.E.
        • McCall L.
        • Beitsch P.
        • et al.
        Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
        Ann Surg. 2010; 252 (discussion 432–3): 426-432
        • Giuliano A.E.
        • Hunt K.K.
        • Ballman K.V.
        • et al.
        Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
        JAMA. 2011; 305: 569-575
        • Giuliano A.E.
        • Morrow M.
        • Duggal S.
        • Julian T.B.
        Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?.
        Clin Exp Metastasis. 2012; 29: 687-692
      1. NCCN. National Comprehensive Cancer Network clinical practice guidelines in oncology. Breast Cancer, ver. 1, 2012.

        • Pepels M.J.
        • de Boer M.
        • Bult P.
        • et al.
        Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.
        Ann Surg. 2012; 255: 116-121
        • Coutant C.
        • Olivier C.
        • Lambaudie E.
        • et al.
        Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study.
        J Clin Oncol. 2009; 27: 2800-2808
        • Mittendorf E.A.
        • Hunt K.K.
        • Boughey J.C.
        • et al.
        Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
        Ann Surg. 2012; 255: 109-115
        • Tsujimoto M.
        • Nakabayashi K.
        • Yoshidome K.
        • et al.
        One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients.
        Clin Cancer Res. 2007; 13: 4807-4816
        • Tamaki Y.
        • Akiyama F.
        • Iwase T.
        • et al.
        Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay.
        Clin Cancer Res. 2009; 15: 2879-2884
        • Edge S.B.
        • Byrd D.R.
        • Compton C.C.
        • Fritz A.G.
        • Greene F.L.
        • Trotti A.
        American Joint Committee on Cancer Staging Manual.
        7th ed. Springer, New York, NY2010
        • Osako T.
        • Iwase T.
        • Kimura K.
        • Masumura K.
        • Horii R.
        • Akiyama F.
        Incidence and possible pathogenesis of sentinel node micrometastases in ductal carcinoma in situ of the breast detected using molecular whole lymph node assay.
        Br J Cancer. 2012; 106: 1675-1681
        • Osako T.
        • Iwase T.
        • Kimura K.
        • et al.
        Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology.
        Cancer. 2011; 117: 4365-4374
        • Osako T.
        • Iwase T.
        • Kimura K.
        • Yamashita K.
        • Horii R.
        • Akiyama F.
        Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular method.
        Br J Cancer. 2011; 105: 1197-1202
        • Notomi T.
        • Okayama H.
        • Masubuchi H.
        • et al.
        Loop-mediated isothermal amplification of DNA.
        Nucleic Acids Res. 2000; 28: E63
        • Mori Y.
        • Nagamine K.
        • Tomita N.
        • Notomi T.
        Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation.
        Biochem Biophys Res Commun. 2001; 289: 150-154
        • Pesek S.
        • Ashikaga T.
        • Krag L.E.
        • Krag D.
        The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.
        World J Surg. 2012; 36: 2239-2251
        • Vegue L.B.
        • Rojo F.
        • Hardisson D.
        • et al.
        Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study.
        Diagn Mol Pathol. 2012; 21: 69-76
        • Viale G.
        • Maiorano E.
        • Pruneri G.
        • et al.
        Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy.
        Ann Surg. 2005; 241: 319-325
        • Klein C.A.
        Parallel progression of primary tumours and metastases.
        Nat Rev Cancer. 2009; 9: 302-312
        • Cserni G.
        Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification.
        J Clin Pathol. 2012; 65: 193-199
        • Jakub J.W.
        • Bryant K.
        • Huebner M.
        • et al.
        The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes.
        Ann Surg Oncol. 2011; 18: 86-93
        • Stitzenberg K.B.
        • Meyer A.A.
        • Stern S.L.
        • et al.
        Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden.
        Ann Surg. 2003; 237 (discussion 612–3): 607-612
        • Neri A.
        • Marrelli D.
        • Roviello F.
        • et al.
        Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.
        Ann Surg Oncol. 2005; 12: 246-253
        • Gruber G.
        • Bonetti M.
        • Nasi M.L.
        • et al.
        Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
        J Clin Oncol. 2005; 23: 7089-7097
        • Iken S.
        • Schmidt M.
        • Braun C.
        • Valentino A.
        • Lehr H.A.
        • Schaefer S.C.
        Absence of ectopic epithelial inclusions in 3904 axillary lymph nodes examined in sentinel technique.
        Breast Cancer Res Treat. 2012; 132: 621-624
        • Maiorano E.
        • Mazzarol G.M.
        • Pruneri G.
        • et al.
        Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies.
        Am J Surg Pathol. 2003; 27: 513-518
        • Tamaki Y.
        • Sato N.
        • Homma K.
        • et al.
        Routine clinical use of the one-step nucleic acid amplification assay for detection of sentinel lymph node metastases in breast cancer patients: results of a multicenter study in Japan.
        Cancer. 2012; 118: 3477-3483